⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
REGN News
Regeneron Pharmaceuticals Inc
SEPTEMBER 14, 2026 REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces
businesswire.com
REGN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
accessnewswire.com
EYPT
REGN
Shareholders of Regeneron Pharmaceuticals, Inc. (REGN): Protect Your Rights Before September 14, 2026 - Contact Levi & Korsinsky
accessnewswire.com
REGN
Pomerantz LLP Updates Shareholders on Legal Action Brought Against Regeneron Pharmaceuticals, Inc. – REGN
accessnewswire.com
REGN
REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Investors of Regeneron Pharmaceuticals, Inc. to Contact the Firm Today!
accessnewswire.com
REGN
Hereditary Transthyretin Amyloidosis Market Insight, Epidemiology, and Market Forecast - 2036 Now Available Reveals Why a $3B Market Is Racing Toward a One-Time Curative Gene-Editing Therapy
globenewswire.com
NTLA
REGN
ALNY
IONS
PFE
Shareholders of Regeneron Pharmaceuticals, Inc. (REGN): Protect Your Rights Before September 14, 2026 - Contact Levi & Korsinsky
accessnewswire.com
REGN
REGN INVESTOR ALERT: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead the Regeneron Class Action Lawsuit
prnewswire.com
REGN
REGN LAWSUIT ALERT: Levi & Korsinsky Notifies Regeneron Pharmaceuticals, Inc. Investors - Lead Plaintiff Deadline September 14, 2026
accessnewswire.com
REGN
REGN ALERT: Hagens Berman Alerts Regeneron Pharmaceuticals, Inc. (REGN) Investors to Pending Securities Fraud Class Action Amid Disclosures About Key Trial's Protocol and Ultimate Failure
prnewswire.com
REGN